<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473768</url>
  </required_header>
  <id_info>
    <org_study_id>ID ITM202007</org_study_id>
    <nct_id>NCT04473768</nct_id>
  </id_info>
  <brief_title>Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children</brief_title>
  <acronym>DeNTS</acronym>
  <official_title>Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children in Sub-Saharan Africa: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital St. Luc Kisantu, République Democratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream&#xD;
      infection, display high levels of antibiotic resistance and have a high case fatality rate&#xD;
      (15%). In Kisantu hospital in the Democratic Republic of Congo (DR Congo), NTS account for&#xD;
      75% of bloodstream infection in children and many children are co-infected with Plasmodium&#xD;
      falciparum (Pf) malaria. NTS bloodstream infection presents as a non-specific severe febrile&#xD;
      illness, which challenges early diagnosis and, as a consequence, prompt and appropriate&#xD;
      antibiotic treatment.Moreover, at the first level of care, frontline health workers have&#xD;
      limited expertise and diagnostic skills and, as a consequence, clinical danger signs that&#xD;
      indicate serious bacterial infections are often overlooked.&#xD;
&#xD;
      Basic handheld diagnostic instruments and point-of-care tests can help to reliably detect&#xD;
      danger signs and improve triage, referral and the start of antibiotics, but there is need for&#xD;
      field implementation and adoption to low-resource settings. Further, it is known that some&#xD;
      clinical signs and symptoms are frequent in NTS bloodstream infections. The integration of&#xD;
      these clinical signs and symptoms in a clinical decision support model can facilitate the&#xD;
      diagnosis of NTS bloodstream infections and target antibiotic treatment.&#xD;
&#xD;
      The investigators aim to develop such a clinical decision support model based on data from&#xD;
      children under five years old admitted to Kisantu district referral hospital in the&#xD;
      Democratic republic of the Congo. While developing the model, the investigators will focus on&#xD;
      the signs and symptoms that can differentiate NTS bloodstream infection from severe Pf&#xD;
      malaria and on the clinical danger signs that can be assessed by handheld diagnostic&#xD;
      instruments and point-of-care tests. The deliverable will be a clinical decision support&#xD;
      model ready to integrate in an electronic decision support system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive signs and symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Identify clinical signs and symptoms predictive for and differentiate between:&#xD;
1.1. NTS bloodstream infection 1.2. severe Pf malaria mono-infection 1.3. NTS/Pf malaria co-infection 1.4. other-pathogen bloodstream infections 1.5. other causes of febrile illness requiring hospital admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contribution of handheld diagnostics and point-of-care tests to NTS bloodstream infection diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the contribution of handheld diagnostic instruments and point-of-care tests to the detection of danger signs associated with NTS bloodstream infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical decision support model for NTS bloodstream infection</measure>
    <time_frame>12 months</time_frame>
    <description>Develop a clinical decision support model for diagnosis of NTS bloodstream infection based on the predictive clinical signs and symptoms associated with NTS bloodstream infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contribution of handheld diagnostics and point-of-care tests to bloodstream infection diagnosis</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the contribution of handheld diagnostic instruments and point-of-care tests to the detection of danger signs associated with all pathogen bloodstream infection (NTS and other-pathogen bloodstream infections combined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical decision support model for bloodstream infection</measure>
    <time_frame>12 months</time_frame>
    <description>Develop a clinical decision support model for diagnosis of bloodstream infection caused by all pathogens (NTS and other pathogens combined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Case fatality</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the clinical signs and symptoms associated with case fatality in NTS bloodstream infection and all pathogen bloodstream infections (NTS and other pathogen combined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geographical clustering</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the geographical clustering of cases with NTS bloodstream infection</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Bloodstream Infection</condition>
  <condition>Salmonella Bacteremia</condition>
  <condition>Malaria,Falciparum</condition>
  <condition>Severe Malaria</condition>
  <arm_group>
    <arm_group_label>NTS bloodstream infection</arm_group_label>
    <description>growth of NTS in blood culture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTS/Pf malaria co-infection</arm_group_label>
    <description>concurrence of current Pf malaria infection and NTS bloodstream infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other pathogen bloodstream infections</arm_group_label>
    <description>growth of a pathogen other than NTS in blood culture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Pf malaria mono-infection</arm_group_label>
    <description>defined according to WHO-criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other causes of febrile illness requiring hospital admission</arm_group_label>
    <description>Current Pf malaria infection: see above&#xD;
Recent Pf malaria infection: see above&#xD;
Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests&#xD;
If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study site: Pediatric ward of St. Luc general referral hospital in Kisantu health zone&#xD;
        (Province Kongo Central, DR Congo), further referred to as &quot;Kisantu Hospital&quot;&#xD;
&#xD;
          -  Capacity: 100 beds, bed occupancy reaches up to 180%&#xD;
&#xD;
          -  Financial system: Flat fees per admission (10$)&#xD;
&#xD;
          -  Ongoing blood culture surveillance study:&#xD;
&#xD;
               -  Routine free-of-charge blood culture sampling &amp; work-up coordinated by INRB/ITM&#xD;
&#xD;
               -  Since 2017, blood culture surveillance as a part of typhoid conjugate vaccine&#xD;
                  study&#xD;
&#xD;
          -  Epidemiological context:&#xD;
&#xD;
               -  High burden of non-typhoidal Salmonella (NTS) bloodstream infections&#xD;
&#xD;
               -  High Plasmodium falciparum (Pf) malaria endemicity&#xD;
&#xD;
               -  High prevalence of malnutrition&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be a child of &gt; 28 days and &lt; 5 years old&#xD;
&#xD;
          2. Be admitted to Kisantu Hospital&#xD;
&#xD;
          3. Having a blood cultured sampled according to the criteria for suspected bloodstream&#xD;
             infection embedded in the blood culture surveillance, i.e. presence of objective&#xD;
             fever, hypothermia or history of fever during past 48 hours + at least one of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Hypotension, confusion or increased respiratory rate&#xD;
&#xD;
               -  Suspicion of severe localized infection: pneumonia, meningitis, osteomyelitis,&#xD;
                  complicated urinary tract infection, abscess, skin/soft tissue infection or&#xD;
                  abdominal infection&#xD;
&#xD;
               -  Suspicion of typhoid fever&#xD;
&#xD;
               -  Suspicion of severe Pf malaria&#xD;
&#xD;
          4. Having a caregiver willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bieke Tack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bieke Tack, MD</last_name>
    <phone>00323247776</phone>
    <email>btack@itg.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Jacobs, MD, PhD</last_name>
    <phone>003232476630</phone>
    <email>jjacobs@itg.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kisantu general referral hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bieke Tack</last_name>
      <email>btack@itg.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bloodstream infection</keyword>
  <keyword>Salmonella non-typhi</keyword>
  <keyword>Children under five years</keyword>
  <keyword>Clinical decision support</keyword>
  <keyword>Democratic Republic of the Congo</keyword>
  <keyword>Fever</keyword>
  <keyword>Febrile illness</keyword>
  <keyword>Malaria</keyword>
  <keyword>Anemia</keyword>
  <keyword>Malnutrition</keyword>
  <keyword>Bacterial infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

